Václav Navrátil

Václav Navrátil

Auto-generated profile, based on publicly available information

Václav Navrátil

Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, 166 10, Czech Republic

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in International Biodeterioration & Biodegradation
Verified
Journal Article
Closed access
HMHana Marušincová
Hana Marušincová
LHLucie Husárová
Lucie Husárová
JRJan Růžička
Jan Růžička
Marek IngrMarek Ingr
Marek Ingr
VNVáclav Navrátil
Václav Navrátil
MKMarek Koutný
Marek Koutný

8 January 2016 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
PŠPavel Šácha
Pavel Šácha
Tomas KnedlikTomas Knedlik
Tomas Knedlik
JSJiří Schimer
Jiří Schimer
JTJan Tykvart
Jan Tykvart
JPJan Parolek
Jan Parolek
JKJan Konvalinka
Jan Konvalinka
Antibodies are indispensable tools for biomedicine and anticancer therapy. Nevertheless, their use is compromised by high production costs, limited stability, and difficulty of chemical modification. The design and preparation of synthetic polymer conjugates capable of replacing antibodies in biomedical applications such as ELISA, flow cytometry, immunocytochemistry, and immunoprecipitation is reported. The conjugates, named “iBodies”, consist of an HPMA copolymer decorated with low‐molecular‐weight compounds that function as targeting ligands, affinity anchors, and imaging probes. We prepared specific conjugates targeting several proteins with known ligands and used these iBodies for enzyme inhibition, protein isolation, immobilization, quantification, and live‐cell imaging. Our data indicate that this highly modular and versatile polymer system can be used to produce inexpensive and stable antibody substitutes directed toward virtually any protein of interest with a known ligand.

27 September 2014 in The Prostate
Verified
Journal Article
Closed access
PDF file
JTJ. Tykvart
J. Tykvart
VNV. Navrátil
V. Navrátil
FSF. Sedlák
F. Sedlák
ECE. Corey
E. Corey
MCM. Colombatti
M. Colombatti
JKJan Konvalinka
Jan Konvalinka

7 May 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JTJan Tykvart
Jan Tykvart
JSJiří Schimer
Jiří Schimer
AJAndrej Jančařík
Andrej Jančařík
JBJitka Bařinková
Jitka Bařinková
VNVáclav Navrátil
Václav Navrátil
PSPavel Sacha
Pavel Sacha

6 June 2016 in The FEBS Journal
Verified
Journal Article
Closed access
PDF file
MNMichal Navrátil
Michal Navrátil
JTJan Tykvart
Jan Tykvart
JSJiří Schimer
Jiří Schimer
PPPetr Pachl
Petr Pachl
VNVáclav Navrátil
Václav Navrátil
JKJan Konvalinka
Jan Konvalinka

26 September 2016 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
VNVáclav Navrátil
Václav Navrátil
JSJiří Schimer
Jiří Schimer
JTJan Tykvart
Jan Tykvart
Tomas KnedlikTomas Knedlik
Tomas Knedlik
VVViktor Vik
Viktor Vik
PSPavel Sacha
Pavel Sacha
Human diseases are often diagnosed by determining levels of relevant enzymes and treated by enzyme inhibitors. We describe an assay suitable for both ultrasensitive enzyme quantification and quantitative inhibitor screening with unpurified enzymes. In the DNA-linked Inhibitor ANtibody Assay (DIANA), the target enzyme is captured by an immobilized antibody, probed with a small-molecule inhibitor attached to a reporter DNA and detected by quantitative PCR. We validate the approach using the putative cancer markers prostate-specific membrane antigen and carbonic anhydrase IX. We show that DIANA has a linear range of up to six logs and it selectively detects zeptomoles of targets in complex biological samples. DIANA's wide dynamic range permits determination of target enzyme inhibition constants using a single inhibitor concentration. DIANA also enables quantitative screening of small-molecule enzyme inhibitors using microliters of human blood serum containing picograms of target enzyme. DIANA's performance characteristics make it a superior tool for disease detection and drug discovery.